Nanexa

3,84 SEK

+3,78 %

Mindre end 1K følgere

NANEXA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Dividend

Investorkonsensus

+3,78 %

+4,35 %

-13,71 %

+25,70 %

+70,67 %

+235,37 %

-2,04 %

-58,34 %

-53,06 %

Nanexa is a drug delivery company with a proprietary platform used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The company's technology is based on encapsulating drug particles with a thin shell and creating opportunities for pharmaceutical companies to develop new products. Nanexa has collaborations with several pharmaceutical companies, mainly around the Nordic market.

Markedsværdi

657,73 mio. SEK

Aktieomsætning

2,13 mio. SEK

Omsætning

36,15 mio.

EBIT %

-24,26 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

29.4

2026

Delårsrapport Q1'26

12.5

2026

Generalforsamling '26

27.8

2026

Delårsrapport Q2'26

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Pressemeddelelse24.2.2026, 07.15

Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)

Eksterne analyser20.2.2026, 07.41

Nanexa: Funding secured as semaglutide pivot sharpens commercial focus - Emergers

Following the breakthrough license deal with Moderna, a global leader in mRNA therapeutics, in Q4’25, Nanexa now pursues two main tracks to leverage its PharmaShell technology into commercial value creation: the Moderna license development agreement ...

Selskabsmeddelelse19.2.2026, 07.01

Nanexa publishes year-end report and Q4 report 2025

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse27.1.2026, 07.30

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

Eksterne analyser12.12.2025, 07.12

Nanexa: First license with Moderna an important validation of PharmaShell - Emergers

The announcement of Nanexa’s first licensing deal marks a meaningful validation of the PharmaShell platform, as Moderna, a global leader in mRNA therapeutics, commits to test up to five compounds under a structure including USD 3m upfront, up to USD ...

Pressemeddelelse12.12.2025, 07.00

Emergers: Equity Research | NANEXA: First license with Moderna an important validation of PharmaShell

Selskabsmeddelelse10.12.2025, 21.35

Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products

Eksterne analyser7.11.2025, 08.58

Nanexa: Intensified focus on deals amid growing funding pressure - Emergers

Nanexa’s Q3 report underscores a pivotal moment for the company. While interest in its PharmaShell technology remains strong, with advanced business discussions ongoing and an extended evaluation agreement in a multi-billion-dollar indication, the financial...

Pressemeddelelse7.11.2025, 07.00

Emergers: Equity Research | NANEXA: Intensified focus on deals amid growing funding pressure

Selskabsmeddelelse6.11.2025, 07.00

Nanexa publishes interim report for January-September 2025

Pressemeddelelse16.10.2025, 06.25

Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025

Selskabsmeddelelse1.10.2025, 10.40

Nanexa AB changes Certified Adviser to Tapper Partners AB

Pressemeddelelse22.9.2025, 06.00

Nanexa receives Japanese patent approval for specific PharmaShell structure

Eksterne analyser28.8.2025, 06.09

Nanexa: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap - Emergers

Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with Phase I data showing once-monthly liraglutide exposure over 36 days without significant gastrointestinal side effects. The company also gained industry...

Pressemeddelelse28.8.2025, 06.00

Emergers: Equity Research | NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap

Selskabsmeddelelse27.8.2025, 05.00

Nanexa publishes interim report for January-June 2025

Pressemeddelelse8.8.2025, 08.43

Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell® Long-Acting Formulations in a Multi-Billion USD Market

Pressemeddelelse24.6.2025, 06.00

Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago

Pressemeddelelse3.6.2025, 13.10

Nanexa Highlights NEX-22 and PharmaShell® During an Intensive Period of International Exposure

Pressemeddelelse23.5.2025, 07.15

All samples analyzed from the 30 mg dose group in the NEX-22 Phase I study

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.